Melatonin is widely known for regulating the sleep–wake cycle, but its clinical potential extends far beyond circadian support. Synthesized primarily by the pineal gland, and to a lesser extent in peripheral tissues, melatonin functions as a potent antioxidant, an anti-inflammatory and immunomodulatory agent, a neuroprotective molecule, and an adjunctive anticancer therapy.
For clinicians managing complex chronic illness—where chronic inflammation, neurodegeneration, mitochondrial dysfunction, and environmental toxin exposure converge—melatonin represents a low-risk, pleiotropic therapeutic tool with an expanding evidence base.
Anti-Inflammatory and Immunomodulatory Actions
Cytokine Modulation and NF-κB Inhibition
Chronic low-grade inflammation is central to many cardiometabolic, neurodegenerative, autoimmune, and environmental illness presentations. A 2021 meta-analysis of 31 human clinical trials found that melatonin supplementation significantly reduced key pro-inflammatory cytokines, including IL‑1β, IL‑6, and IL‑8, suggesting a direct role in modulating cytokine signaling pathways in humans.¹
Mechanistically, melatonin inhibits NF‑κB activation, thereby downregulating transcription of multiple pro-inflammatory mediators. It also blocks inflammasome activation, reducing IL‑1β production,² and simultaneously scavenges free radicals while upregulating endogenous antioxidant enzymes such as superoxide dismutase and glutathione peroxidase.² This dual role — direct antioxidant activity plus enhancement of intrinsic antioxidant defenses—creates a powerful counterbalance to inflammation driven by oxidative stress.
Protection Against Environmental Toxins and Mycotoxins
For patients with known or suspected environmental toxin exposure, including mycotoxins, melatonin may offer additional benefit. Preclinical work has shown that melatonin reduces oxidative stress, apoptosis, and inflammation induced by mycotoxins such as ochratoxin A.³ In porcine oocytes, melatonin ameliorated ochratoxin A–induced oxidative damage and cell death, highlighting its role in mitochondrial protection and redox balance at the cellular level.³
Although human data specific to mycotoxin illness remain limited, these findings are highly relevant for clinicians treating patients with mold-related illness or chronic environmental exposure who exhibit marked oxidative stress and inflammatory burdens.
Neuroprotective Effects in Clinical Practice
Melatonin readily crosses the blood–brain barrier and exerts multiple actions in the central nervous system, including antioxidant, anti-inflammatory, mitochondrial, and circadian-regulatory effects.
Melatonin in Alzheimer’s Disease and Cognitive Decline
Altered melatonin secretion is associated with neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease, and low nocturnal melatonin may correlate with disease progression and sleep–wake disruption.
A classic case report of monozygotic twins with Alzheimer’s disease found that the twin receiving nightly melatonin experienced significantly slower cognitive decline than the untreated twin.⁴ Although anecdotal, this report helped spark interest in melatonin’s neuroprotective potential. More robust evidence comes from a 2022 network meta-analysis of randomized, placebo-controlled trials in Alzheimer’s dementia, which demonstrated a dose- and duration-dependent association between melatonin treatment and improved overall cognition, particularly in early disease stages.⁶
Multiple Sclerosis and Neurological Function
Beyond cognition, melatonin may support neuromuscular function and quality of life in neuroinflammatory disorders. In a randomized controlled trial of patients living with multiple sclerosis, 3 mg of melatonin daily resulted in clinically meaningful improvements in muscle strength, manual dexterity, postural balance, mood, and cognitive performance.⁵ These findings suggest that even relatively low doses can exert measurable benefits in central nervous system conditions characterized by inflammation, oxidative stress, and mitochondrial dysfunction.
Blood–Brain Barrier Integrity and Acute Neurologic Injury
Melatonin also shows promise in acute neurologic conditions. In patients with hemorrhagic stroke, melatonin supplementation was associated with reduced serum S100B levels—a marker of blood–brain barrier disruption and astrocyte injury.⁷ A systematic review and meta-analysis evaluating melatonin after traumatic brain injury (TBI) found evidence of reduced cerebral edema, significant neuroprotective effects in preclinical models, and potential improvements in cognition and functional outcomes, warranting further clinical study.⁸
For clinicians, these data underscore melatonin’s potential role as an adjunctive therapy in both chronic neurodegeneration and acute neurologic injury, particularly when oxidative and inflammatory cascades drive ongoing damage.
Evidence-Based Benefits of Melatonin
Regulates inflammation at the cellular level • Blocks key inflammatory pathways • Counters toxin-induced inflammation • Slows neurodegeneration and enhances cognition in Alzheimer’s • Improves survival in advanced cancer • Enhances neurological function in MS • Reduces brain inflammation post-injury
Anticancer Properties and Survival Outcomes
Melatonin’s anticancer effects are multifactorial and extend beyond its circadian influence.
Mechanisms of Anticancer Action
Experimental and clinical data point to several key mechanisms. Melatonin modulates hormone signaling, particularly in hormone-dependent cancers, inhibits tumor cell proliferation and angiogenesis, enhances immune surveillance via increased natural killer (NK) cell activity, and promotes apoptosis in malignant cells.⁹ It also appears to protect healthy cells from chemotherapy-induced toxicity while increasing the sensitivity of cancer cells to conventional treatments.
In hormone-dependent cancers such as breast cancer, melatonin has been shown to support apoptotic pathways and may help regulate estrogen signaling, further contributing to its anticancer effect.⁹
Survival Benefits in Advanced Cancer
Two major meta-analyses highlight melatonin’s potential as an adjunct in oncology. A meta-analysis of 10 randomized trials found that melatonin reduced 1‑year mortality by 34% in patients with advanced cancer when used alongside standard therapies.¹⁰ A separate review of 21 trials reported a near doubling of 1‑year survival rates in patients receiving melatonin as adjunctive therapy.¹¹
Despite heterogeneity among studies and the need for more contemporary data, these findings are difficult to ignore in the context of integrative oncology, particularly given melatonin’s favorable safety profile, accessibility, and low cost.
Clinical Use, Dosing, and Safety
Dosing Considerations
Melatonin is a well-established intervention for circadian rhythm support, but its broader benefits often require thoughtful dosing and timing. In adults, a common dosing range is 5–20 mg nightly for systemic anti-inflammatory, neuroprotective, and anticancer support. Lower doses can still be effective in neurology; doses as low as 3 mg nightly have demonstrated significant benefits in patients with multiple sclerosis and early neurodegenerative changes.⁵ ⁶
Evening administration aligns with endogenous melatonin secretion, supports physiologic circadian signaling, and likely optimizes nighttime repair and recovery processes. Clinicians can titrate dose based on clinical response, tolerance, and specific therapeutic targets, whether that is sleep regulation, neuroprotection, or oncology support.
Safety, Side Effects, and Interactions
Melatonin is generally regarded as safe, non-addictive, and well tolerated, even at relatively high doses used in clinical trials. The most commonly reported side effect is drowsiness, particularly if taken late at night or at higher doses. Some patients may also experience vivid dreams, morning grogginess, or mild headaches.
To date, melatonin has not demonstrated significant, clinically problematic drug–drug interactions in the literature. Nonetheless, prudent caution and monitoring are warranted in patients on multiple CNS-active medications or anticoagulants. Its immune-modulatory and antioxidant functions make it particularly attractive for complex chronic illness, where polypharmacy, mitochondrial dysfunction, and chronic immune activation are common.
Clinical Takeaways for Complex Chronic Illness
For clinicians treating patients with complex, multisystem presentations—driven by chronic inflammation, neurodegeneration, environmental toxins, or malignancy—melatonin is a compelling candidate for routine consideration.
At the cellular level, melatonin helps regulate inflammation by reducing IL‑6, IL‑1β, and IL‑8 in humans¹ and by inhibiting both NF‑κB activity and inflammasome activation.² It counters toxin-induced oxidative stress, attenuating oxidative damage and apoptosis from mycotoxins, including ochratoxins, in preclinical models.³ In neurodegenerative disease, both case data and meta-analytic evidence support its role in slowing cognitive decline and improving cognition in early Alzheimer’s disease.⁴ ⁶ In multiple sclerosis, low-dose melatonin improves strength, coordination, balance, mood, and cognition,⁵ while in stroke and TBI it is associated with reduced S100B levels, protection of the blood–brain barrier, and emerging evidence of functional benefit.⁷ ⁸
In oncology, melatonin enhances NK cell activity, promotes tumor cell apoptosis, and protects normal tissues from treatment-related damage.⁹ Meta-analyses report both reduced 1‑year mortality and improved survival in advanced cancer when melatonin is used as an adjunct to standard care.¹⁰ ¹¹
Given its pleiotropic mechanisms, low cost, and strong safety record, melatonin is well positioned to serve as a cornerstone therapy in cases of complex chronic illness—particularly where chronic inflammation is a central driver of pathology, neurodegeneration or cognitive decline is emerging, environmental toxins and mycotoxins contribute to disease burden, or patients are undergoing or recovering from cancer therapy.
Thoughtful incorporation of melatonin into individualized treatment plans—paired with monitoring of clinical response and patient tolerance—offers a pragmatic, evidence-informed strategy to enhance resilience, support repair, and modulate disease-driving pathways.
References
- Cho JH, et al. Anti-inflammatory effects of melatonin: a systematic review and meta-analysis of clinical trials. Brain Behav Immun. 2021;93:245–253.
- Nabavi SM, et al. Anti-inflammatory effects of melatonin: a mechanistic review. Crit Rev Food Sci Nutr. 2019;59(sup1):S4–S16.
- Lan M, Zhang Y, Wan X, Pan MH, Xu Y, Sun SC. Melatonin ameliorates ochratoxin A-induced oxidative stress and apoptosis in porcine oocytes. Environ Pollut. 2020;256:113374.
- Brusco LI, Marquez M, Cardinali DP. Monozygotic twins with Alzheimer’s disease treated with melatonin: Case report. J Pineal Res. 1998;25(4):260–263.
- Jallouli S, et al. Effects of Melatonin Supplementation on Muscle Strength, Manual Dexterity, and Postural Balance in Patients Living with Multiple Sclerosis – A Randomized Controlled Trial. J Diet Suppl. 2025;22(2):236–261.
- Tseng PT, et al. The Dose and Duration-dependent Association between Melatonin Treatment and Overall Cognition in Alzheimer’s Dementia: A Network Meta-Analysis of Randomized Placebo-Controlled Trials. Curr Neuropharmacol. 2022;20(10):1816–1833.
- Sharifnia H, et al. Evaluating the neuroprotective effect of melatonin on patients with hemorrhagic stroke using serum S100B protein. Jundishapur J Nat Pharm Prod. 2021;16(1):e64476.
- Barlow KM, Esser MJ, Veidt M, Boyd R. Melatonin as a Treatment after Traumatic Brain Injury: A Systematic Review and Meta-Analysis of the Pre-Clinical and Clinical Literature. J Neurotrauma. 2019;36:523–537.
- Reiter RJ, et al. Melatonin as a natural antioxidant and anti-inflammatory: molecular mechanisms and clinical implications. Curr Trends Pharmacol. 2020;8:67–78.
- Mills E, et al. Melatonin in the treatment of cancer: a systematic review and meta-analysis. J Pineal Res. 2005;39(4):360–366.
- Wang Y, et al. Melatonin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Oncol Lett. 2017;13(4):1984–1990.
